More on Atypical Fractures of the Femoral Diaphysis
- 17 July 2008
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 359 (3), 316-318
- https://doi.org/10.1056/nejmc080861
Abstract
Our experience has been very similar to that described by Lenart et al. (March 20 issue)1 in their report on atypical fractures of the femoral diaphysis. These fractures have a distinctive pattern and most likely represent completion of a stress fracture ( Figure 1 ). In our series,2 64.3% of the patients had involvement of the contralateral femur. In addition, 76% of the patients had documented prodromal symptoms of thigh pain, vague discomfort, or subjective weakness; these symptoms were often dismissed or treated as symptoms of spinal stenosis. “Giving way” of the involved limb immediately preceded the fall in 23.1% of the patients.3 We suggest that any patient receiving bisphosphonates who has thigh pain should undergo radiographic examination of the femur, and patients with a documented fracture should undergo radiographic examination of the contralateral femur. Prefracture diagnosis is challenging, as is defining the need for prophylactic fixation of a lateral cortical stress reaction that has been characterized by means of computed tomographic and magnetic resonance imaging (MRI) studies as a callus forming over an incomplete stress fracture.Keywords
This publication has 7 references indexed in Scilit:
- Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking AlendronateThe New England Journal of Medicine, 2008
- An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy?Injury, 2008
- Looking beyond low bone mineral density: Multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapyJournal of Endocrinological Investigation, 2007
- Subtrochanteric insufficiency fractures in patients on alendronate therapyThe Journal of Bone and Joint Surgery. British volume, 2007
- Enhancement of Experimental Fracture-Healing by Systemic Administration of Recombinant Human Parathyroid Hormone (PTH 1-34)The Journal of Bone & Joint Surgery, 2005
- Severely Suppressed Bone Turnover: A Potential Complication of Alendronate TherapyJournal of Clinical Endocrinology & Metabolism, 2005
- The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal OsteoporosisThe New England Journal of Medicine, 2003